Use of low cell dose for unmanipulated donor lymphocyte for management of cytomegalovirus infection: a single-center experience
Yükleniyor...
Dosyalar
Tarih
2020
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Although advancements have been made in monitoring and preventing viral infections in HSCT patients, CMV reactivation still remains a critical post-transplant complication. Adoptive cell therapy is an alternative to pharmacotherapy of CMV infection in refractory patients. We retrospectively reviewed CMV infection cases after allogeneic HSCT who received U-DLI as treatment. In total, five pediatric patients between the ages of 0.5-16 years that received U-DLI for a post-HSCT CMV infection were evaluated. The dose of CD3+ lymphocytes administered in DLI was 5 × 104 /kg, except in one patient transplanted from his sibling. One patient, who was transplanted from an unrelated donor, received U-DLI from his haploidentical mother. CMV titers dramatically reduced after U-DLI. If the availability of CMV-specific CTL is an issue, we propose that one should consider using the U-DLI therapy with low cell dose from a seropositive donor. In case the stem cell donor is seronegative and a seropositive donor is unavailable, using the U-DLI therapy from seropositive, haploidentical donors is a promising way of treatment. More studies need to be conducted to further confirm the safety and efficacy of this treatment procedure.
Açıklama
Anahtar Kelimeler
Cytomegalovirus, Donor Lymphocyte Infusion, Hematopoietic Stem Cell Transplantation
Kaynak
Pediatr Transplant
WoS Q Değeri
Q4
Scopus Q Değeri
N/A
Cilt
Sayı
Künye
Uygun, V., Karasu, G., Daloğlu, H., Öztürkmen, S., Yalçın, K., Çelen, S. S., & Yeşilipek, A. (2020). Use of low cell dose for unmanipulated donor lymphocyte for management of cytomegalovirus infection: A single-center experience. Pediatric transplantation, e13882. Advance online publication. https://doi.org/10.1111/petr.13882
